BioXcel Capital Stock vs Net Tangible Assets Analysis
BTAI Stock | USD 0.44 0.04 8.33% |
BioXcel Therapeutics financial indicator trend analysis is way more than just evaluating BioXcel Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioXcel Therapeutics is a good investment. Please check the relationship between BioXcel Therapeutics Capital Stock and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
Capital Stock vs Net Tangible Assets
Capital Stock vs Net Tangible Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioXcel Therapeutics Capital Stock account and Net Tangible Assets. At this time, the significance of the direction appears to have strong relationship.
The correlation between BioXcel Therapeutics' Capital Stock and Net Tangible Assets is 0.78. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of BioXcel Therapeutics, assuming nothing else is changed. The correlation between historical values of BioXcel Therapeutics' Capital Stock and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of BioXcel Therapeutics are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Capital Stock i.e., BioXcel Therapeutics' Capital Stock and Net Tangible Assets go up and down completely randomly.
Correlation Coefficient | 0.78 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most indicators from BioXcel Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioXcel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.The BioXcel Therapeutics' current Selling General Administrative is estimated to increase to about 66.7 M, while Issuance Of Capital Stock is projected to decrease to under 21.1 M.
BioXcel Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
BioXcel Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioXcel Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 36.4M | 219.9M | 239.4M | 205.9M | 73.7M | 100.3M | |
Total Current Liabilities | 8.5M | 11.8M | 16.7M | 32.9M | 27.3M | 28.6M | |
Total Stockholder Equity | 26.9M | 206.7M | 221.7M | 76.8M | (56.5M) | (53.7M) | |
Common Stock Shares Outstanding | 16.3M | 21.7M | 26.4M | 28.0M | 29.1M | 21.5M | |
Other Stockholder Equity | 83.6M | 345.5M | 467.4M | 488.3M | 534.1M | 560.8M | |
Total Liab | 9.5M | 13.2M | 17.8M | 129.1M | 130.2M | 136.7M | |
Total Current Assets | 34.1M | 217.1M | 233.0M | 202.9M | 72.1M | 98.2M | |
Property Plant Equipment | 2.2M | 1.3M | 1.3M | 1.1M | 1.2M | 855.5K | |
Other Current Liab | 3.5M | 6.9M | 11.4M | 22.3M | 13.2M | 8.5M | |
Net Tangible Assets | 26.9M | 206.7M | 221.7M | 76.8M | 88.3M | 89.5M | |
Property Plant And Equipment Net | 2.2M | 2.8M | 2.5M | 2.1M | 1.5M | 1.6M | |
Retained Earnings | (56.7M) | (138.9M) | (245.8M) | (411.5M) | (590.6M) | (561.1M) | |
Accounts Payable | 5.0M | 4.0M | 4.7M | 10.2M | 13.7M | 14.3M | |
Cash | 32.4M | 213.1M | 233.0M | 193.7M | 65.2M | 107.4M | |
Non Current Assets Total | 2.3M | 2.9M | 6.5M | 3.0M | 1.6M | 2.3M | |
Liabilities And Stockholders Equity | 36.4M | 219.9M | 239.4M | 205.9M | 73.7M | 112.8M | |
Non Current Liabilities Total | 1.0M | 1.4M | 1.1M | 96.2M | 102.9M | 108.1M | |
Other Current Assets | 1.7M | 6.9M | 3.8M | 6.9M | 4.9M | 3.4M | |
Property Plant And Equipment Gross | 2.2M | 2.8M | 3.1M | 2.9M | 2.7M | 1.9M | |
Common Stock | 16K | 18K | 24K | 28K | 30K | 31.5K | |
Net Debt | (31.4M) | (211.5M) | (231.6M) | (99.6M) | 36.2M | 38.0M | |
Cash And Short Term Investments | 32.4M | 213.1M | 233.0M | 193.7M | 65.2M | 122.7M | |
Common Stock Total Equity | 16K | 18K | 24K | 28K | 32.2K | 22.7K | |
Capital Surpluse | 83.6M | 345.5M | 467.4M | 488.3M | 561.5M | 589.6M | |
Net Invested Capital | 26.9M | 206.7M | 221.7M | 169.8M | 44.1M | 41.9M | |
Net Working Capital | 25.6M | 205.2M | 220.1M | 170.0M | 44.9M | 42.6M | |
Retained Earnings Total Equity | (56.7M) | (138.9M) | (245.8M) | (411.5M) | (370.4M) | (351.9M) |
Currently Active Assets on Macroaxis
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.04) | Revenue Per Share 0.074 | Quarterly Revenue Growth 1.416 | Return On Assets (0.64) | Return On Equity (17.67) |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.